Akso Files IPO Prospectus: Powering Pharma Compliance Digitalization with 100% Implementation Success

In the wave of compliance-driven digital and intelligent transformation in the pharmaceuticals industry, Chongqing Akso has become an undisputed "hot favorite" — Qilu Pharmaceutical, Hengrui Pharma, CSPC, Kelun Pharmaceuticals, and other leading pharmaceutical enterprises have extended their olive branches to establish deep cooperation. To date, Akso has successfully assisted over 150 pharmaceutical companies in implementing integrated digital platforms and group-wide deployment solutions, achieving the industry's first-ever 100% project implementation and launch rate—a remarkable feat with consistently high customer satisfaction.

In the current era where numerous players are competing in the pharmaceutical digitalization track, why do leading pharmaceutical companies all favor Akso? What "trump card" does this company hold that allows it to take the lead in the field of pharmaceutical compliance and digital intelligence, opening up a new blue ocean for the industry? The answer lies in its hardcore product strength, solid operational foundation, and precise grasp of industry needs.

As a benchmark in the pharmaceutical quality management track, Akso's core competitiveness lies primarily in the technical barriers built with its proprietary core technology that are difficult for the industry to surpass. The self-developed Akso eGxP^®One-stop Solution, Powered by the Exclusive Zero-code Unified Data Platform Akso Gaia, Deeply Integrates Six Core Systems Including GMP Document Management, Quality Management, and Training Management, Achieving Full-module Interconnection. This Solution Effectively Eliminates the Industry-wide Issue of "Data Silos" Common in Traditional Single-point Systems. More Thoughtfully, the Entire Process Requires No Manual Re-entry, Which Not Only Prevents Human Errors at the Source but Also Significantly Enhances Cross-process and Cross-departmental Collaborative Management Efficiency for Enterprises. For Pharmaceutical Companies Pursuing High Efficiency and Compliance, This is Undoubtedly a Must-have Solution.

In product development, Akso has taken a "difficult but correct" path. Compared to the commonly seen Class 5 custom-developed software in the industry, Akso has invested several times the R&D costs to create the more technically demanding Class 4 configurable software. The advantages of this investment are immediately apparent: traditional custom-developed software not only has a long deployment cycle but also poses higher regulatory compliance risks. In contrast, Akso’s configurable software, with its flexible, building-block-like configuration, can quickly meet customers' personalized needs while offering strong scalability, low learning costs, and out-of-the-box usability, significantly reducing the detours pharmaceutical companies face in their compliant digital transformation.

What makes pharmaceutical companies more assured is that Akso’s products have achieved "global compatibility" in terms of compliance. Meeting the dual certifications of ISO27001 Information Security Management and ISO9001 Quality Management, they fully align with authoritative regulations from the FDA, EU, WHO, NMPA, and other domestic and international bodies. They can also synchronize with global regulatory updates in real time, transforming pharmaceutical companies from passive compliance in the past to proactive compliance management. Their intelligent data governance capabilities can automatically complete data standardization processes, perfectly meeting ALCOA+ full-dimensional compliance requirements, turning scattered compliance data into core digital assets for enterprises.

What is particularly remarkable is that Akso has precisely addressed the industry pain point of "international products being unsuitable for local conditions, and domestic products lacking compatibility." The product is based on the differentiated needs of pharmaceutical companies, offering highly flexible personalized customization services and deeply integrating industry best practices. It not only possesses international top-tier quality but also perfectly adapts to the actual business scenarios of domestic pharmaceutical enterprises. Its technological advancement, GMP compliance, and user-friendly operation have thus gained high recognition from leading customers. A QA manager from a top pharmaceutical company even stated frankly that among various similar systems both domestically and internationally, Akso’s overall performance is undoubtedly the optimal choice.

If hardcore products are Akso's "hard power," then its steady business philosophy and mature service system are the "ballast stones" ensuring its long-term stability and success. Akso's core leadership team has over three decades of deep experience in the pharmaceuticals industry, with an incisive understanding of industry development patterns and compliance standards, as well as precise control over market demands. This has enabled the company to build a mature and comprehensive operational system, reinforcing its strategic foundation for sustainable growth.

In an industry where many companies are pursuing short-term profits, Akso has consistently adhered to long-term thinking, strategically positioning itself across the entire business chain. It has established a full-process service loop that encompasses customized solution design, efficient deployment and implementation, and routine post-launch maintenance. Relying on a highly responsive local service mechanism, a professional team provides one-on-one dedicated support for clients throughout the entire journey, addressing the industry-wide issue of "unfinished projects" at its root. This is the key to Akso achieving a 100% project implementation and launch success rate. Genuine professional services have earned Akso the long-term trust of its clients, fostering a high-loyalty customer base. In turn, a stable core team and mature service model have become the pillars of Akso's healthy operations, enabling the company to maintain steady growth amidst fierce industry competition.

The current track of digital intelligence in pharmaceutical compliance is ushering in unprecedented development opportunities. Heavyweight policies such as the "Implementation Plan for Digital Intelligence Transformation in the Pharmaceutical Industry (2025-2030)" are being rolled out intensively. Digital compliance in the pharmaceutical industry has long since evolved from an "optional action" for enterprises to a "rigid requirement" for survival and development. A comprehensive regulatory system has opened up vast market space for the industry. As compliance supervision enters the "deep water zone," traditional fragmented compliance solutions can no longer meet the needs of pharmaceutical companies, making one-stop solutions an inevitable choice for breaking through industry challenges.

At the same time, the digital divide within the industry has further unleashed Akso's market potential. Currently, apart from leading pharmaceutical companies, most small and medium-sized enterprises have yet to implement professional quality management systems. A vast amount of market demand is waiting for capable companies to tap into. With its cutting-edge products, a mature service system, and deep understanding of industry needs, Akso is undoubtedly a standout player in this market competition.

Backed by policy dividends, rooted in market demand, and armed with two "trump cards" — product and service — Akso's path forward has become clear. In the future, this benchmark company, which has always been deeply engaged in the field of pharmaceutical compliance and digital intelligence, will continue to empower more pharmaceutical enterprises with one-stop solutions, helping the industry achieve compliance and digital transformation. With strong momentum, it will lead the pharmaceutical industry into a new journey of high-quality development!